Creo Medical Group (CREO)

Sector:

Health Care

Index:

FTSE AIM All-Share

 35.25p
   
  • Change Today:
      0.000p
  • 52 Week High: 48.10
  • 52 Week Low: 23.25
  • Currency: UK Pounds
  • Shares Issued: 361.48m
  • Volume: 741,956
  • Market Cap: £127.42m

Creo device used in 'groundbreaking' lung cancer procedure

By Josh White

Date: Friday 01 Mar 2024

LONDON (ShareCast) - (Sharecast News) - Creo Medical Group announced a significant milestone in the field of minimally-invasive surgical endoscopy for cancer patients on Friday, with its 'MicroBlate Flex' device.
The AIM-traded company announced that professor Pallav Shah and Dr Christopher Orton, specialists from the Royal Brompton Hospital, had successfully conducted the world's first robotic-guided microwave ablation of lung tissue concurrently with a diagnostic procedure.

It said the pioneering procedure, using its MicroBlate Flex device, targeted a 27mm cancerous nodule within a patient's lung.

The achievement was considered a notable advancement in the medical community's ability to diagnose, stage, and treat lung cancer in a single sitting.

In a statement, Dr Orton emphasised the potential of the innovative approach, saying the "potential to combine the diagnosis, staging, and treatment of lung cancer in one procedure offers significant benefit to patients".

Creo said the procedure, conducted at the Royal Brompton Hospital in London, reportedly lasted just three minutes.

"Creo has been pioneering minimally invasive surgical endoscopy for pre-cancer and cancer patients for years, and implementing our technology into robotic application is a key goal for us as the adoption of this technology continues to grow exponentially," said chief executive officer Craig Gulliford.

"We are incredibly proud that our MicroBlate Flex technology has been able to make this world-first possible.

"The potential for these technologies to combine precise robotically guided lung cancer diagnosis with the ablation of cancerous tissue in one session is transformational."

Gulliford said that could "dramatically improve" outcomes for lung cancer patients, and had the potential to remove "long and worrying" delays between diagnosis and treatment.

"This is the beginning of an exciting programme and the team have done a terrific job in reaching this point."

At 1411 GMT, shares in Creo Medical Group were up 0.84% at 30p.

Reporting by Josh White for Sharecast.com.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

CREO Market Data

Currency UK Pounds
Share Price 35.25p
Change Today 0.000p
% Change 0.00 %
52 Week High 48.10
52 Week Low 23.25
Volume 741,956
Shares Issued 361.48m
Market Cap £127.42m

CREO Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
65.13% below the market average65.13% below the market average65.13% below the market average65.13% below the market average65.13% below the market average
69.7% below the sector average69.7% below the sector average69.7% below the sector average69.7% below the sector average69.7% below the sector average
Price Trend
15.11% above the market average15.11% above the market average15.11% above the market average15.11% above the market average15.11% above the market average
27.78% above the sector average27.78% above the sector average27.78% above the sector average27.78% above the sector average27.78% above the sector average
Income Not Available
Growth
15.65% below the market average15.65% below the market average15.65% below the market average15.65% below the market average15.65% below the market average
27.78% below the sector average27.78% below the sector average27.78% below the sector average27.78% below the sector average27.78% below the sector average

What The Brokers Say

Strong Buy 1
Buy 0
Neutral 0
Sell 0
Strong Sell 0
Total 1
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

CREO Dividends

No dividends found

Trades for 28-May-2024

Time Volume / Share Price
16:17 15 @ 35.29p
15:52 1,500 @ 35.29p
15:49 2,000 @ 35.30p
15:06 3,246 @ 35.05p
13:36 5,681 @ 35.20p

CREO Key Personnel

CEO Craig Jonathan Gulliford
CFO Richard John Rees

Top of Page